Develops antibody-based therapeutics for cancer and autoimmune diseases.
Jun 2026Revenue $37.1M/yrExpenses $193M/yr
No trendCash runway ≈ 1.5 years from Jun 2026
Figures by year
When will Zymeworks be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $37.1M and expenses $193M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $106M | $199M | −$92.5M |
| Dec 2024 | $76.3M | $213M | −$137M |
| Dec 2023 | $76.0M | $214M | −$138M |
| Dec 2022 | $412M | $282M | $131M |
| Dec 2021 | $26.7M | $242M | −$216M |
| Dec 2020 | $39.0M | $226M | −$187M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.